Immunotherapy of renal cell carcinoma.
Immunologic approaches to the therapy of metastatic renal cell carcinoma have provided moderate improvement in response rates for a disease that is extremely resistant to all forms of treatment. This article reviews recent clinical efforts using immunotherapy for renal cell carcinoma, including the adoptive transfer of cytotoxic killer cells and/or the use of biologic response modifiers, such as interferon and interleukin-2.
Haas
G P
GP
Department of Urology, Wayne State University School of Medicine, Detroit, Michigan.
Hillman
G G
GG
Redman
B G
BG
Pontes
J E
JE
D002292:Carcinoma, Renal Cell / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive; D007370:Interferon Type I / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D011994:Recombinant Proteins
D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins